A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
← catalyst calendarNCT07589595 · readout ≤ 743 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
350estimated
Sites
71
Countries
Japan, South Korea, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-20 | actual | When the study began enrolling |
| Primary completion | Aug 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cognitive Dysfunction
- Lewy Body Disease
- Synucleinopathies
- Amyloid
Interventions
- Drug: Donanemab — also filed as LY3002813
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline on Clinical Dementia Rating - Sum of Boxes (CDR-SB)
measured Baseline through Week 52
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed